麦迪霉素3-O-酰基转移酶在螺旋霉素链霉菌F21中酰化特性

Acylation Specificity of Midecamycin 3-O-acyltransferase within Streptomyces spiramyceticus F21

摘要:

螺旋霉素(SP)与麦迪霉素(MD)均为16元环大环内酯类抗生素, 并且结构非常相似。螺旋霉素含有3个组分,其结构差异表现在16元内酯环C3上的一个取代基的差异, SP I组分为羟基、SP II组分羟基乙酰化、SP III组分羟基丙酰化; 麦迪霉素是以麦迪霉素A1为主要组分的多组分抗生素, 麦迪霉素16元内酯环C3上连接的均为丙酰化羟基。已知这类抗生素16元内酯环C3羟基酰化是由一种称为3-O-酰基转移酶的蛋白催化完成。本研究将螺旋霉素产生菌—Streptomyces spiramyceticus F21中的螺旋霉素3-O-酰基转移酶基因用Streptomyces mycarofaciens ATCC 21454中的麦迪霉素3-O-酰基转移酶基因原位替换后, 发现所产生的螺旋霉素仍然含有3个组分, 并且螺旋霉素III组分也不是主要组分, 说明麦迪霉素3-O-酰基转移酶在螺旋霉素产生菌—S. spiramyceticus F21中不具有16元内酯环C3羟基丙酰化特异性以及酰化高效性, 也提示其在麦迪霉素产生菌中的丙酰化特异性和高效性可能与该菌株(种)的特性有关。

Abstract:

Spiramycin and midecamycin are 16-membered macrolide antibiotics with very similar chemical structures. Spiramycin has three components, namely spiramycin I, II and III. Spiramycin II and III are, respectively, the O-acetyl and propionyl derivatives at C3-hydroxyl group of spiramycin I. Midecamycin has four components, and the C3-hydroxyl group of midecamycin is all O-propionylated. The enzyme adding acyl group(s) at the C3-hydroxyl group during the biosynthesis of spiramycin and midecamycin is 3-O-acyltransferase. The 3-O-acyltransferases for spiramycin and midecamycin are also very similar, and presume to function when exchanged. To explore whether the 3-O-acyltransferase for midecamycin biosynthesis hold still the character of selective and efficient propionylation for spiramycin I at its C3-hydroxyl group, we inserted mdmB, the 3-O-acyltransferase gene from Streptomyces mycarofaciens ATCC 21454 for midecamycin biosynthesis, into a mutant strain of S. spiramyceticus F21, in which the 3-O-acyltransferase gene for spiramycin biosynthesis, sspA, was deleted; and the mdmB was integrated exactly into the chromosomal site where the sspA was deleted. We name this “hybrid” strain as SP-mdmB. HPLC analysis of the spiramycin produced by SP-mdmB showed that spiramycin I was still the major component, although the relative proportions of both spiramycin II and III increased significantly. We thus conclude that MdmB from Streptomyces mycarofaciens ATCC 21454 for midecamyicn biosynthesis do not hold the character of selective and efficient propionylation for spiramycin I within S. spiramyceticus F21, and this character is possibly limited in Streptomyces mycarofaciens ATCC 21454 for midecamycin biosynthesis.